dry-slide clinical chemistry [letter]

NLM AIDSLINE Dry-slide clinical chemistry [letter] Ashby JP; Blundell G
January 30, 1991

Lancet. 1990 Oct 6;336(8719):886. Unique Identifier : AIDSLINE Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL Chemistry, Clinical/INSTRUMENTATION/METHODS Human *Specimen Handling Time Factors LETTER JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 COLORADO: Boulder Groups Honor More Than 150 Local AIDS Victims PENNSYLVANIA: Area Residents Screened for Hepatitis C on Sunday COLORADO: Peer to Peer: Teens Work to Educate Peers on Pregnancy, STDs at CCHS OREGON: Portland Barefoot 3 x 3 Benefit Tournament to Draw Hundreds to Northeast Portland TEXAS: Temple - Wellness and Sexual Health Classes Helping Kids to Abstain CONNECTICUT: Yale Researchers Urge More Street Work When Studying People With Both HIV, Hepatitis C JAMAICA: AIDS Awareness Workshop Organised for High-School Students EUROPE: EU Issues Stringent Sharps Regulations CALIFORNIA: $50,000 Prisoner Prescription: Inmates Get Expensive Hepatitis C Treatment Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Recent Events Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic(R), SB-728-T Ascletis Gains China Market Rights from Janssen to a Clinical Stage HIV Protease Inhibitor Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection Clinical Care Options to be the Official Provider of Online Scientific Analysis of the 7th International AIDS Society Conference On HIV Pathogenesis, Treatment and Prevention FLORIDA: Condom Nation Slides into Town Sangamo Presents New Clinical Data at CROI 2013 Demonstrating Persistent Immune System Improvements After Treatment With ZFN Therapeutic® SB-728-T India: HRW Letter to Justice Verma, Chair of the Commission on reforms on sexual assault and Former Chief Justice of the Supreme Court of India Sangamo Presents New Clinical Data at CROI 2013 Demonstrating Persistent Immune System Improvements After Treatment With ZFN Therapeutic® SB-728-T
Information in this article was accurate in January 30, 1991. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.